ProKidney, a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), has announced the appointment of Bruce Culleton as executive vice president of clinical development and commercialisation. Culleton, who will report to CEO Tim Bertram, joins ProKidney after more than two decades in industry and academia with a primary focus on kidney health.
Bertram said: “I am thrilled to welcome Bruce to the ProKidney team. His extensive experience in the identification and management of CKD and development of novel solutions for CKD patients will be invaluable as we continue advancing the development of React toward a potential commercial launch. I look forward to working closely with Bruce to optimally position each of our ongoing clinical studies for successful outcomes and preparing for ProKidney’s anticipated shift to a commercial organisation.”
A press release outlines that Culleton joins ProKidney from CVS Kidney Care, a wholly owned subsidiary of CVS Health, where he was most recently vice president and general manager. Previously, he served as vice president and chief medical officer at CVS Kidney Care. Before joining CVS Health, he was vice president, global clinical development and worldwide vice president, Medical Affairs, Medication and Procedural Solutions at Becton Dickinson (BD); and previously vice president, Renal Therapeutic Area at Baxter Healthcare. Prior to beginning his industry career in 2007, Culleton was a clinical associate professor in the Department of Medicine at the University of Calgary (Calgary, Canada).
Culleton himself added: “With Phase 3 clinical development well underway and initial interim data expected in late 2024, ProKidney is rapidly approaching an important inflection point. I am excited to work with Tim and the rest of the team as we continue advancing our mission of improving the lives of patients with CKD.”
